E
Eliane Gluckman
Researcher at University of Paris
Publications - 694
Citations - 48573
Eliane Gluckman is an academic researcher from University of Paris. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 112, co-authored 679 publications receiving 46415 citations. Previous affiliations of Eliane Gluckman include Medical College of Wisconsin & Leiden University.
Papers
More filters
Journal ArticleDOI
Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission
RogerH. Herzig,A. John Barrett,Eliane Gluckman,Steven J. Jacobsen,Tohru Masaoka,N. K. C. Ramsay,Olle Ringdén,FerdinandE. Zwaan,MortimerM. Bortin,Blume Kg,MaryM. Horowitz,Alberto M. Marmont,H. Grant Prentice,A. A. Rimm,Bruno Speck,Robert Peter Gale +15 more
TL;DR: Whether patients with high-risk ALL should receive transplants during first remission or should initially receive chemotherapy, with transplantation being reserved for patients who relapse is determined.
Journal ArticleDOI
Bone Marrow Transplantation in Severe Aplastic Anaemia: a Survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.) *
TL;DR: The overall 1 year survival was 41.2%.
Journal ArticleDOI
Hypersensitivity pneumonitis related to imatinib mesylate.
Anne Bergeron,Emmanuel Bergot,G. F. Vilela,Lionel Ades,Agnès Devergie,Helene Esperou,Gérard Socié,Fabien Calvo,Eliane Gluckman,P. Ribaud,Ph. Rousselot,A. Tazi +11 more
Journal Article
Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients.
TL;DR: Prophylaxis against toxoplasmosis with weekly administration of pyrimethamine/sulfadoxine (Fansidar) was assessed for efficacy and toxicity in bone marrow transplant (BMT) recipients over a 21 month period.
Journal ArticleDOI
Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry
J Donadieu,G. Michel,Etienne Merlin,Pierre Bordigoni,B Monteux,Blandine Beaupain,Guy Leverger,J. P. Laporte,Olivier Hermine,Agnes Buzyn,Yves Bertrand,Jean-Laurent Casanova,Thierry Leblanc,Eliane Gluckman,Alain Fischer,Jean-Louis Stephan +15 more
TL;DR: It is concluded that HSCT is feasible for patients with SDS who develop bone marrow failure or malignant transformation, and the overall 5-year event-free survival rate is 60±15%.